BSE filing, NSE: JUBLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹923.80
- Market cap
- ₹14,714 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 41.8×Sector 48.7×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Board Meeting Date
Jubilant Pharmova has scheduled a board meeting for November 13, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing is a Regulation 29 advance intimation only.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Jubilant Pharmova Credit Rating
Jubilant Pharmova received a credit rating of IND AA+/Stable from India Ratings and Research for its proposed Non-Convertible Debentures worth ₹1,400 Crore.
- Value
- ₹1,400 Cr
Jubilant Pharmova Credit Rating
Jubilant Pharmova received an [ICRA]AA+ (Stable) rating from ICRA for its proposed non-convertible debentures. This confirms the credit assessment for the upcoming debt instrument.
Jubilant Pharmova Debt & Borrowing: ₹800 Cr
Jubilant Pharmova board approved NCD issuance up to ₹800 crore on private placement basis. Postal ballot also sought for NCD authorization up to ₹2,500 crore.
- Value
- ₹800.0 Cr
- Execution
- Upto five years from the Deemed Date of Allotment
Jubilant Pharmova Capacity Expansion: ₹633.1 Cr Investment
Jubilant Pharmova's Radiopharma business will invest CAD 94.5 million (approx. ₹633 Crore) to expand production capacity at its Kirkland facility, aiming to double RUBY-FILL® production.
- Value
- ₹633.1 Cr
- production capacity
- 2.0 times
Other other announcement announcements
All →LCC Projects Other Announcement
LCC Projects filed its CARE Ratings monitoring agency report for the quarter ended 30 September 2026 on IPO proceeds. The report states all utilisation matches the offer document with no deviations.
Advait Energy Transitions Other Announcement
Advait Energy Transitions shareholding pattern for quarter ended 30 September 2026 shows promoter holding of 66.72%. Routine SEBI Reg 31 disclosure with no transaction or capital event.
Narayana Hrudayalaya Other Announcement
Narayana Hrudayalaya filed a Regulation 54 security cover statement for the quarter ended September 30, 2026. The NCDs are unsecured, so the cover requirement does not apply.
Lyka Labs Other Announcement
Lyka Labs filed its quarterly shareholding pattern for the period ended September 30, 2026 under Regulation 31. Promoter and public holdings are reported as of that date, with no transaction or corporate event.
Mobavenue AI Tech Other Announcement
Mobavenue AI Tech filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter and promoter group hold about 65.6% of the equity.
IITL Projects Other Announcement
IITL Projects confirmed it need not file Regulation 23 related party disclosures for the half-year ended 30 September 2026. The small-company exemption applies under Regulation 15(2).